Kornimate/medical-research-clean huggingface dataset:
effects of different oxygen concentrations on lung ultrasound score during spontaneous ventilation

Conditions: Pulmonary Atelectasis

Summary: the goal of this study is to observe the effects of different oxygen concentrations during preoxygenation in spontaneous breathing patients with modified lung ultrasound scores before induction of general anesthesia. preoxygenation is a routine and recommended procedure for patients undergoing general anesthesia. atelectasis is a common side effect of general anesthesia and usage of high concentration oxygen is a probable cause of it. using lower oxygen concentrations in preoxygenation may help reducing the atelectasis and it can be assessed by lung ultrasound.

preoxygenation is the process of supplying the patient a high inspired fraction of oxygen prior to an airway intervention or induction of general anesthesia. prolonging safe apnea duration is the primary aim of preoxygenation and preoxygenation is recommended for all patients before induction of general anesthesia. atelectasis is the most common postoperative pulmonary complication and is associated with usage of high inspired fraction of oxygen. modified lung ultrasound scoring is an effective and noninvasive method to determine atelectasis. in this study we will observe the effects of different oxygen concentrations during preoxygenation before induction of general anesthesia in spontaneous breathing patients with modified lung ultrasound scores . patients undergoing general anesthesia for elective surgery meeting the criteria will be acknowledged about the study. after written consents are taken patients will be randomised into two groups by coin method. one group will receive %80 oxygen for 3 minutes and other group will receive %100 oxygen for 3 minutes during preoxygenation. each participants demographic data will be collected. 12 quadrants of thorax divided by midsternal line, anterior axillary and posterior axillary lines will be examined by the usage of modified lung ultrasound score before and at the end of preoxygenation for all individuals. randomisation, lung ultrasound scoring and preoxygenation will be done by different experienced anesthesiologists so the observers of this study would be blinded for the results. patients will be blinded for the concentration of oxygen. modified lung scores of each group would be compared at the end of the study.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists score i and ii * being a candidate to elective surgery under general anesthesia exclusion criteria: * patients with any pulmonary disease * patients who had pulmonary infection in the past 3 months * patients who had a surgery in the past 3 months * patients who had a multitrauma in the past 3 months * patients who have a body mass index over 30 * pregnants * patients who have diaphragma hernia * patients who have gastroesophageal reflux disease

Keywords: atelectasis preoxygenation lung ultrasound general anesthesia
belatacept for renal transplant recipients with delayed graft function

Conditions: Delayed Graft Function

Summary: currently looking for individuals that have received a kidney transplant, are experiencing delayed graft function (dgf), and meet the criteria for study participation.

patients who undergo kidney transplantation require long term immunosuppressive therapy (therapy that reduces your body's ability to respond to anything foreign) to prevent damage to the graft, and some experience delayed graft function (dgf, a condition in which the transplanted kidney does not function properly) after transplantation. this study is being conducted to determine if kidney transplant recipients with delayed graft function (dgf) who are switched to the immunosuppressive regimen of belatacept with mycophenolate and steroid will recover from delayed graft function (dgf) in less time (which could potentially lower the risk of rejection associated with delayed graft function) than kidney transplant recipients with delayed graft function (dgf) who remain on the current standard immunosuppressive regimen (standard of care).

Eligibility criteria:
inclusion criteria: 1. signed written informed consent 2. deceased donor renal transplant recipient 3. men and women, aged 18-60 years of age exclusion criteria: 1. seronegative or unknown ebv serostatus 2. patients unwilling or incapable of providing informed consent. 3. patients with active tuberculosis or positive tb test without evidence of infection treatment. 4. patients with demonstrated acute rejection on first biopsy evaluation for delayed graft function; second transplant or multiple organ transplant; patients more than 12 days post renal transplant prior to enrollment 5. evidence of sepsis or other clinical indicators deemed clinically contraindicated for study enrollment by the primary physician 6. inadequate vein access to receive monthly iv infusions 7. prior proven allergy or severe adverse drug reaction to mycophenolate, steroid or belatacept preventing therapy. 8. pregnant women or women of child bearing age not willing to commit to dual contraception prophylaxis 9. use of alemtuzumab (campath 1-h©), basilixumab (simulect©) and daclizumab (zenapax©) are not permitted in this protocol; use of other immunosuppressive agents must be limited to those specified in this protocol. 10. prisoners or subjects who are involuntarily incarcerated. 11. subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness. 12. pre-sensitized patients with alloscreen antibody levels of 80% or more class i or class ii

Keywords: dialysis kidney transplant immunosuppressive therapy delayed graft function belatacept
erectile dysfunction in good prognosis prostate cancer : comparison between brachytherapy and stereotactic body radiotherapy

Conditions: Prostate Cancer

Summary: the tempos-genitourinary group (getug) study is a multicenter, medico-economic study comparing brachytherapy to sbrt in low and intermediate risk prostate cancer, particularly focused on the issue of erectile dysfunction. a total of 240 potent patients are randomized in two arms. the experimental arm consists of sbrt delivering 7.25 gy per fraction, in five fractions, corresponding to a total dose of 36.25 gy to the prostate. the control arm consists of brachytherapy by iodine 125 delivering 144 gy to the prostate. the main objective of this health economics study is to perform a cost-utility analysis of sbrt compared to "standard" iodine 125 brachytherapy in low-risk prostate cancer, 3 years after treatment. the endpoint is the incremental cost-utility ratio (icur) between sbrt and brachytherapy as primary criterion, expressed in cost per quality adjusted life year (qaly) gained. cost-effectiveness analyses are performed as secondary objective with incremental cost-effectiveness ratios (icers) expressed as cost per erectile dysfunction avoided and cost per life year gained. a long term evaluation is also performed, including a cost-utility, cost-effectiveness and budget impact analysis at 5 years, a comprehensive assessment of the erectile dysfunction up to 5 years after treatment, an evaluation of acute and late genito-urinary (gu) and gastro-intestinal (gi) toxicities, and of quality of life up to 5 years after treatment. eight patients/year/center are expected to be recruited in 2 years in about twenty participating centers. in total, to our knowledge, this study will be the first health economic evaluation which compares sbrt versus iodine 125 brachytherapy in low risk and intermediate risk prostate cancer. both cost-utility and cost-effectiveness analyses will also provide useful and complementary information to decision makers in order (i) to recommend the best strategy to adopt; (ii) to estimate the budget impact on the french national health insurance of the generalization of the cost-effective strategy. finally, this study will allow to assess and compare accurately the erectile dysfunction after both treatment modalities.


Eligibility criteria:
main inclusion criteria * biopsy proven prostate adenocarcinoma, * low risk prostate cancer according to d'amico (t1-t2a and psa \<10 ng/ml, and gleason score 6) or intermediate risk prostate cancer according d'amico but excluding tumor with gleason score 7 (4 + 3), * indication of a curative treatment by brachytherapy validated in multidisciplinary consultation meeting, main exclusion criteria * androgen deprivation therapy, * contraindication for prostate iodine 125 brachytherapy (prostate volume \> 50 cc, impossibility if general anesthesia). * contraindication for resonance magnetic imagery (rmi) (claustrophobia, pacemaker) * participation to another research which could have an impact on the study treatment and the outcomes

Keywords: sbrt brachytherapy localized low-risk and intermediate risk prostate cancer
nanocrystalline hydroxyapatite bone substitute for treating periodontal intrabony defects

Conditions: Chronic Periodontitis

Summary: the present clinical trial included 20 patients (11 females and 9 males, aged 36 to 56 years) suffering from moderate or advanced chronic periodontitis. subjects were recruited from the outpatient clinic, department of oral medicine and periodontology, faculty of dentistry, cairo university. this clinical trial was meant to assess clinically and radiographically the possible predictable results regarding the use of nanocrystalline hydroxyapatite bone graft substitute together with open flap debridement versus open flap debridement alone in the treatment of periodontal intrabony defects.

periodontal intrabony defects in patients with moderate or advanced chronic periodontitis were treated with open flap debridement only in the control group while open flap debridement and nanocrystalline hydroxyapatite bone graft substitute was performed for the intervention group. probing pocket depth, clinical attachment level, gingival index, plaque index, gingival recession and bone defect area were assessed at baseline and six months post surgically to evaluate the possible improvement in the clinical and radiographic outcomes.

Eligibility criteria:
inclusion criteria: * systemically healthy patients * diagnosed with moderate to advanced chronic periodontitis * periodontal defects with at least one site with probing pocket depth (ppd) ≥ 5mm, clinical attachment loss (cal) ≥ 4mm and two or three-walled intra-bony defects ≥ 3mm * evidence of intrabony defects using periapical radiographs exclusion criteria: * teeth with suprabony defects or 1-wall intrabony defects * pregnant or lactating women * patients taking any medication 3 months prior to the study * patients receiving any periodontal treatment 6 months prior to study initiation * former or current smokers.

Keywords: periodontal intrabony defects
use of transvenous pacing wire during minimally invasive port access aortic valve surgery

Conditions: Aortic Valve Disease

Summary: the study is being done to determine if the endovent pulmonary catheter kit, used for port access surgery, can be used as a passageway for a pacing wire. the study hypothesis is that the endovent kit can be used effectively as a passageway for a pacing wire system.

many times cardiac surgery requires the use of epicardial pacing in order to wean the patient from bypass. during minimally invasive port access valve surgery, it may not be possible to place the leads on the surface of the heart because of the limited surgical exposure. in this case, transvenous pacing is used. minimally invasive port access surgery uses specially designed, fda approved catheters for the procedure. we wish to review the effectiveness of being able to place the wires through the catheters and pace the patient.

Eligibility criteria:
inclusion criteria: * \>= 18 years of age patients having aortic valve port access surgery scheduled for minimally invasive port access aortic valve study patient must agree to study participation; understand and sign the written informed consent exclusion criteria: * \< 18 years of age patients are excluded if they are not having minimaly invasive aortic valve surgery not having aortic valve port access surgery

Keywords: minimally invasive surgery port access surgery heart pacing wire mics cardiac bypass epicardial pacing pacing catheter pacing wire pacing swan pacing pulmonary catheter pulmonary endovent catheter aortic valve surgery edwards lifesciences
norepinephrine infusion different doses in cesarean delivery

Conditions: Cesarean Section Complications

Summary: three doses (0.025 mcg/kg/min, 0.050 mcg/kg/min, and 0.075 mcg/kg/min) of norepinephrine will be compared for prophylaxis against post-spinal anesthesia hypotension during cesarean delivery.

maternal hypotension is a common complication after spinal anesthesia for cesarean delivery (cd). using vasopressors have been considered a gold standard for prevention of post-spinal hypotension (psh) during cd. norepinephrine (ne) is a potent vasopressor characterized by both α adrenergic agonist activity in addition to a weak β adrenergic agonist activity; thus, ne is considered a vasopressor with minimal cardiac depressant effect; these pharmacological properties would make ne an attractive alternative to phenylephrine and ephedrine (the most commonly used vasopressors in obstetric anesthesia). norepinephrine has been recently introduced as a prophylactic vasopressor during cd with promising results; however, the optimum dose for efficient prophylaxis with the least side effects is not known. in this study, three doses (0.025, 0.050, 0.075 mcg/kg/min) of norepinephrine will be compared for prophylaxis against psh during cd.

Eligibility criteria:
inclusion criteria: * full term * singleton * pregnant women * scheduled for elective cesarean delivery exclusion criteria: * cardiac morbidities * hypertensive disorders of pregnancy * peripartum bleeding * baseline systolic blood pressure (sbp) \< 100 mmhg * body mass index \> 35 will be excluded from the study.
childhood obesity management using innovative digital technology

Conditions: Obesity Prevention; Child Behaviour; Health Behaviour Change; Obesity and Overweight; Physical Activity

Summary: the project will evaluate the short- and long-term effects of a 10-week family healthy living program (fhlp). the program is designed for families with children ages 8-12 years old who are at risk for being above a healthy weight and who would like support with healthy living habits such as physical activity and healthy eating. families will participate together, with both parents and children being involved in the program. fhlp participants will receive 9 weekly 2-hour online group sessions with a facilitation team as well as additional web-based resources. they will be compared to a control group of participating families who will be offered only the self-guided web-based resources. this will help us see the impact of offering facilitated fhlp group sessions versus only offering resources online. the fhlp is 10 weeks long, but participants will be followed for 12 months in total so that researchers can look at the long-term impact of participation. all participating families from both groups will be asked to complete surveys and provide child height and weight measurements at four timepoints: before beginning the program, immediately after completing the program, at 6-months post-program, and at 12-months post-program. children will also be given fitbit activity watches to measure their daily step counts at each timepoint. researchers will compare survey responses, child growth patterns, and fitbit step counts between the fhlp participants and the control group to see whether participating in the fhlp helps families improve their healthy living habits more than only offering a similar curriculum of healthy living resources online for families to access on their own.


Eligibility criteria:
inclusion criteria: * children must be aged 8-12 years with at least one primary caregiver who agrees to participate with them. more than one child per parent will be able to participate if the child meets the inclusion criteria. * children must have a bmi ≥ 85th percentile for age and sex. exclusion criteria: * children below the 85th percentile bmi. * the inability to communicate (speak, read, and write) in english. * any conditions that prevent children from being physically active.
a study to determine the recommended dose and schedule, and evaluate the safety and preliminary efficacy of mezigdomide in combination with elranatamab in participants with relapsed and/or refractory multiple myeloma

Conditions: Multiple Myeloma

Summary: the purpose of this study is to evaluate the preliminary safety and determine the rp2d of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (rrmm).


Eligibility criteria:
inclusion criteria: * age ≥18 with history of relapsed and refractory multiple myeloma (rrmm) treated with 2 to 4 prior lines of anti-myeloma therapy (phase 1) or 1 to 3 prior lines of anti-myeloma therapy (phase 2). * measurable mm by local laboratory. * eastern cooperative oncology group performance status (ecog ps) of 0 to 1. * adherence to contraception requirements. exclusion criteria: * prior treatment with mezigdomide. * prior treatment with t cell engaging or t cell engager (tce). * prior treatment with b cell-maturation antigen (bcma)-targeting therapy, with the exception of participants who have received autologous bcma-targeted cart-cell therapy\> 6 months from the start of study therapy * other protocol-defined inclusion/exclusion criteria apply.
effects of desmopressin on blood loss and the quality of the surgical field during endoscopic sinus surgery

Conditions: Patients Undergoing Endoscopic Sinus Surgery

Summary: bleeding during functional endoscopic sinus surgery (fess) is a challenge for both surgeons and anesthesiologists despite several measures available for improving the surgical field. this study was conducted to evaluate the effect of desmopressin on blood loss and the quality of the surgical field in fess.

desmopressin, a synthetic analogue of vasopressin, has been employed as a non-transfusional treatment for hemophilia and von willebrand's disease. hemostatic effects of desmopressin include: 1) an increase in plasma factors through endogenous release of coagulation factor viii, von willebrand factor and tissue plasminogen activator; 2) an increase in platelet adhesiveness; and 3) a reduction in bleeding time. randomized, double-blind studies have been performed on patients undergoing various types of surgical procedures. a study in patients undergoing orthognathic surgery showed a significant reduction in intraoperative blood loss and a study in patients undergoing lumbar fusion concluded that desmopressin was effective in reducing intraoperative blood loss. the purpose of this study was to investigate the effect of administration of desmopressin on intraoperative blood loss in patients undergoing fess.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists physical status i-ii * aged 18-60 years exclusion criteria: * patients receiving anticoagulants * medically important liver or kidney dysfunction * significant heart disease * allergy to desmopressin
effect of pexidartinib on the way the body processes cyp3a4 and cyp2c9 substrates (pharmacokinetics)

Conditions: Drug Interaction Potential

Summary: this study has two parts. part 1 will evaluate how pexidartinib affects the way the body processes cyp3a4 and cyp2c9 substrates using midazolam and tolbutamide, respectively, as probe agents. part 2 will test the efficacy and safety of pexidartinib treatment in various tumor types. in part 2, the same participants will continue to receive pexidartinib twice daily. participants will be allowed to continue using pexidartinib as long as the participant derives benefit.


Eligibility criteria:
inclusion criteria: * is the age of majority in country of residence * has a diagnosis of: 1. tenosynovial giant cell tumor (tgct), which is associated with severe morbidity or functional limitations and for whom surgery is not an option (prior pexidartinib is permitted for tgct patients unless ineffective or not tolerated and there has been a washout period of at least 4 weeks) 2. kit-mutant tumor, including melanoma or gastrointestinal stromal tumor (gist), for which there is no standard systemic therapy, or 3. other solid tumors (all comers) for which there is no standard systemic therapy and there is a rationale for use of pexidartinib at the investigator's discretion * if a female of childbearing potential, had a negative serum pregnancy test within 14 days before enrollment, or within 72 hours before enrollment where required * is a non-sterile male or female willing to use of one of the protocol-defined highly effective contraception methods: 1. intra-uterine device (nonhormonal or hormonal) 2. sexual abstinence (only if this is in line with the patient's current lifestyle) 3. barrier methods (eg, condom, diaphragm) used in combination with hormonal methods associated with inhibition of ovulation * is a surgically sterile male or female, or is postmenopausal for at least 1 year, at least 50 years of age, with a follicle-stimulating hormone level \> 40 milli-international units per ml (miu/ml) * has adequate hematologic, hepatic, and renal function as defined by the protocol * is able and willing to follow all study procedures * has provided a signed informed consent exclusion criteria: * is pregnant or breastfeeding * is unable to swallow oral medication * is unable to follow study procedures * is taking or has taken any medications or therapies outside of protocol-defined parameters * has any disease or condition that, per protocol or in the opinion of the investigator, might affect: 1. safety and well-being of the participant or offspring 2. safety of study staff 3. analysis of results

Keywords: tenosynovial giant cell tumors (tgct) kit-mutant melanoma kit-mutant gastrointestinal stromal tumor (gist) cocktail drug-drug interaction (ddi)
platelet rich plasma for carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: carpal tunnel syndrome (cts) is the most common peripheral entrapment neuropathy with involving compression of the median nerve in the carpal tunnel. although many conservative managements of cts, the effectiveness of these methods is insignificant or only persist for a short duration. the platelet rich plasma (prp) is a new and potential treatment for patients with kinds of musculoskeletal disorders and recent reports showed being beneficial for peripheral neuropathy in animal studies. since 2014, four small clinical trials showed the positive effect of prp in peripheral neuropathy. among these studies, two small trials showed beneficial effect of prp for patients with mild cts. however, the definite clinical effect of prp for peripheral neuropathy from currently published studies is unclarified because these studies enrolled a few patients and lacked long-term follow-up (no more than 6 months follow-up).

after obtaining written informed consent, patients of clinically diagnosed with bilateral cts were randomized into intervention and control side. intervention group received one-dose ultrasound-guided prp injection and control group received one-dose ultrasound-guided normal saline injection. no additional treatment after injection through the study period. the primary outcome is boston carpal tunnel syndrome questionnaire (bctq) and secondary outcomes include visual analog scale (vas), cross-sectional area (csa) of the median nerve, sensory nerve conduction velocity of the median nerve, and finger pinch strength. the evaluation was performed pretreatment as well as on the 2nd week, 1st, 3rd, 6th month and one year after the treatment.

Eligibility criteria:
inclusion criteria: * age between 20-80 year-old. * diagnosis was confirmed using an electrophysiological study exclusion criteria: * cancer * coagulopathy * pregnancy * inflammation status * polyneuropathy, brachial plexopathy * thoracic outlet syndrome * previously undergone wrist surgery or steroid injection for cts

Keywords: platelet rich plasma perineural injection therapy hydrodissection